- ￥1500
- ATCC、DSMZ、ECACC、RIKEN
- 江苏
- CH1374
- 2026年03月26日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
LCC
- 库存：
100万
- 供应商：
欣润生物
- 肿瘤类型：
是
- 细胞类型：
细胞系
- ATCC Number：
CH1374
- 品系：
人
- 组织来源：
喉癌
- 相关疾病：
人喉癌
- 物种来源：
人源
- 免疫类型：
不详
- 细胞形态：
上皮型
- 是否是肿瘤细胞：
是
- 器官来源：
详见说明
- 运输方式：
新鲜或干冰
- 年限：
成年
- 生长状态：
贴壁生长
- 规格：
T25方瓶
- 细胞名称：LCC细胞（人喉癌细胞）
- 形态：上皮型，贴壁生长
- 含量：>1x106 个/瓶
- 污染：支原体、细菌、酵母和真菌检测为阴性
- 规格：T25瓶或者1mL冻存管包装
二、细胞接收后的处理：
1、贴壁细胞
- 收到T25方瓶细胞后，请检查是否漏液，如果漏液，请拍照片发给我们（冻存管细胞收到后直接37℃水浴复苏或直接放置于液氮中长期储存）。
- 请先在显微镜下确认细胞生长状态，去掉封口膜并将T25瓶置于37℃培养约2-3h。
- 弃去T25瓶中的培养基，换用新鲜的完全培养基。
- 如果细胞长满（90%以上）请及时进行细胞传代。
- 接到细胞次日，请检查细胞是否污染，若发现污染或疑似污染，请及时与我们取得联系。
2、悬浮细胞
- 收到细胞后，请检查是否漏液，如果漏液，请拍照片发给我们。
- 请先在显微镜下确认细胞生长状态，去掉封口膜并将15ml离心管置于37℃培养约2-3h。
- 1200rpm离心5min，弃去15ml离心管中的培养基，细胞沉淀用新鲜的完全培养基重悬并培养。
- 如果细胞长满（90%以上）请及时进行细胞传代。
- 接到细胞次日，请检查细胞是否污染，若发现污染或疑似污染，请及时与我们取得联系。
本公司的细胞培养操作规程，供参考
一、培养基及培养冻存条件准备：
- 准备RPMI-1640培养基，85%；优质胎牛血清，15%。
- 培养条件： 气相：空气，95%；二氧化碳，5%。 温度：37℃，培养箱湿度为70%-80%。
- 冻存液：90%血清，10%DMSO，现用现配。液氮储存。
对于贴壁细胞，传代可参考以下方法：
- 弃去培养上清，用不含钙、镁离子的PBS润洗细胞1-2次。
- 加2ml消化液（0.25%Trypsin-0.53mM EDTA）于培养瓶中，置于37℃培养箱中消化2-3分钟，然后在显微镜下观察细胞消化情况，若细胞大部分变圆并脱落，迅速拿回操作台，轻敲几下培养瓶后加入3ml此细胞的培养基终止消化。
- 轻轻吹打后吸出，移入15ml离心管中，在1200RPM条件下离心5分钟，弃去上清液，加入1mL培养液后吹匀。
- 移入到事先准备好的含有5ml培养基的T-25培养瓶中或含有14ml培养基的T-75培养瓶中培养。
3）细胞冻存：待细胞生长状态良好时，可进行细胞冻存。贴壁细胞冻存时，先要消化处理并进行细胞计数。消化方法按照细胞传代方法的1-3步骤进行，最后的重悬液使用血清。悬浮细胞直接计数后离心，用血清重悬浮，加DMSO至最终浓度为10%。加入DMSO后迅速混匀，按每1ml的数量分配到冻存管中。本公司按每个冻存管细胞数目大于1X106个细胞冻存。
注意事项：
1. 收到冻存管细胞后，若发现干冰已挥发干净、冻存管瓶盖脱落、破损及细胞有污染，请立即与我们联系。
2. 所有动物细胞均视为有潜在的生物危害性，必须在二级生物安全台内操作，并请注意防护，所有废液及接触过此细胞的器皿需要灭菌后方能丢弃。
3. 细胞用途：仅供科研使用。
发货方式：
复苏后发货：我们复苏细胞后发货，货期一周左右，免运费。（气温较好建议复苏后发货）
冻存发货(干冰运输）：需额外增加干冰运费，选择干冰运输的我们发两管细胞，为了保证客户接种可靠性多发一管。（气温低于0℃须冻存发货）
细胞发货采取专业的运输包装，并选择最快捷的运输方式（顺丰速运或其他空运快递）
Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Somatic LKB1 serine/threonine kinase alterations are rare in sporadic cancers, with the exception lung adenocarcinoma, but no mutations in squamous cell or large cell primary carcinoma were discovered. We screened the LKB1 gene in 129 primary nonsmall cell lung carcinomas, adjacent healthy lung tissue, and control blood samples. Forty-five percent of nonsmall cell lung tumors harbored either intron or exon alterations. We identified R86G, F354L, Y272Y and three polymorphisms: 290+36G/T, 386+156G/T, and 862+145C/T (novel). R86G (novel) and F354L mutations were found in six squamous cell carcinomas and three large cell cancer carcinomas, but not in the adjacent healthy tissue or controls samples. The F354L mutation was found in advanced squamous cell carcinomas with elevated COX-2 expression, rare P53, and no K-RAS mutation. Results indicate that the LKB1 gene is changed in a certain proportion of nonsmall cell lung tumors, predominately in advanced squamous lung carcinoma. Inactivation of the gene takes place via the C-terminal domain and could be related to mechanisms influencing tumor initiation, differentiation, and metastasis.
An LCC-Based String-to-Cell Battery Equalizer With Simplified Constant Current Control
Constant current equalization can effectively mitigate the inconsistency of battery strings in a fast manner. In this manuscript, a constant current string-to-cell battery equalizer with an open-loop current control is proposed. The equalization scheme is based on LCC multiresonant topology. It utilizes a common equalizer unit shared by each unbalanced cell to transfer energy from the entire string to a single cell. A constant balancing current is achieved with simple fixed-frequency open-loop control. The equalization speed is determined by the predesigned balancing current. Design considerations of the proposed equalizer are analyzed in detail, which ensure zero-voltage switching among all> s during the equalization process. An experimental platform to balance four lithium-ion battery cells is designed to verify the system performance. Experimental results validate the functionality and analysis of this equalizer. Compared with the conventional architecture, the proposed architecture exhibits a high efficiency, low components count, and obviously reduced control complexity.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1. Chicken intestinal epithelial cells were obtained from NEWGAINBIO company. Cells were cultured on 37℃, with 5% CO2, in the Ham’s F-12 Nutrient (DMEM/12) that contained the following supplementations: fetal bovine serum (5%), in-sulin (5 µg/mL), transferrin (5 µg/mL), selenium (5 ng/mL), epidermal growth factor (5 ng/mL) and penicillin-streptomycin (100–100 U/mL) for cell culturing (full DMEM/12). Experiments were performed with chicken intestinal epithelial cells and working solutions were prepared with plain DMEM/12 without supplementation. For the investigations, cells were seeded onto 96-well, 24-well or 6-well polystyrene cell culture plates.
2. Primary hVICs (passage 2) were cultured to 50–60% confluence and infected with pGMLV-SV40T-puro lentivirus (NewgainBio, Wuxi, China) at a multiplicity of infection of 80 supplemented with 5 µg/mL polybrene (Sigma-Aldrich, Buchs, Switzerland).
3. Tissue was cultured until cells became visible around the tissue, and when the fusion reached 90% (FIGURE 1A) §ask ¦lled with the prepared culturing medium was sent to the company for further immortalisation. Cell immortalisation was done for cell stability and longer-term use. Immortalised cells were cultured with 10% FBS and 1% PS in the DMEM medium. After the cells multiplied and merged, they were routinely passed and grown ( NEWGAINBIO Inc. Wuxi, Jiangsu, China) (FIGURE 1B-C).
4. Mouse primary cultured renal vascular ECs and VSMCs were obtained from Newgainbio company, which were tested by Factor VIII and α-smooth muscle actin (α-SMA), the marker of ECs and VSMCs. RNeasy Mini Kit was used for RNA extraction, and the above protocols were repeated.
5. Porcine primary colon epithelial cells (Newgainbio company, Wuxi,China) were cultured in Dulbecco's Modified Eagle's Medium (Solarbio, Beijing, China) containing 10 % fetal bovine serum (BioInd, Kiryat shmona, Lsrael) at 37 ◦C and 5 % CO2 humidity.
STM：傅阳心、侯玉柱等发现放疗与免疫治疗的交汇点，兵家必争之地竟是这群细胞
癌 (LCC) 小鼠模型的脾脏及其细胞组成。结果发现，LCC 小鼠发生了脾肿大，但是这种肿大能够在放疗后基本恢复正常。同时，Ter119+CD71+ EPCs 在放射治疗后，其比例也明显降低，基本恢复到基线水平。此外，在其他肿瘤模型，如 MC38 结肠癌和 B16-SIY 黑色素瘤模型，也观察到了类似的放疗后 Ter 细胞显著减少的现象，表明放疗诱导的 Ter 细胞减少并不局限于某种肿瘤类型。 图片来源：Sci. Transl. Med 放疗通过干扰素和 T 细胞介导对 Ter 细胞的削弱 接下
魔高一尺，道高一丈！清华大学徐萌团队发现能量代谢与肿瘤免疫逃逸的关系
, GZMB, and PRF1）定义了 cytotoxic T lymphocyte (CTL) score，反映肿瘤浸润 CD8+ T 细胞的功能。 研究发现在表观转录组调控因子中，RNA 去甲基化酶 FTO 与 CTL score 呈现负相关。为了检测肿瘤细胞的 FTO 表达是否影响 T 细胞介导的抗肿瘤功能，研究人员在 B16-OVA 黑色素瘤细胞和肺癌细胞系 LLC 中对 FTO 进行敲降。研究人员将 B16-OVA 和 LLC 接种到小鼠体内，发现 Fto-Kd 细胞产生的肿瘤生长速度明显减慢
（红细胞压积）、MCV（红细胞平均体积）、MCH（红细胞平均血红蛋白量）、MCHC（红细胞平均血红蛋白浓度）、PCL（血小板数）、W�SCR（白细胞小细胞或淋巴细胞百分比）、W�LCR（白细胞大细胞中性粒细胞百分比）、W�SCC（白细胞小细胞或淋巴细胞绝对值）、W�LCC（白细胞大细胞或中性粒细胞绝对值）、RDW�CV（红细胞分布宽度变异系数）、PDW（血小板分布宽度）、MPV（血小板平均体积）。此十五项指标各自都有正常参考值预先输入仪器电脑中，若高于或低于正常范围，该项目测定值前面会出现
